Boston, MA -- (SBWIRE) -- 09/27/2013 -- Global Markets Direct's, 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Bladder Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bladder Cancer.
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Shionogi & Co., Ltd., Eli Lilly and Company, Viralytics Ltd., GlaxoSmithKline plc, Seattle Genetics, Inc., Bioniche Life Sciences, Inc., Bavarian Nordic A/S, Biotest AG, Samyang Corporation, Eisai Co., Ltd., MDRNA, Inc., Taiho Pharmaceutical Co., Ltd., Advaxis, Inc., AEterna Zentaris Inc., Alnylam Pharmaceuticals, Inc, Oncogenex Pharmaceuticals, Inc., Sanochemia Pharmazeutika AG, PharmaGap Inc., Quest PharmaTech Inc., Med Discovery SA, Altor BioScience Corporation, Telormedix SA, Gene Signal International SA., Heat Biologics, Inc., MacroGenics, Inc., Innate Therapeutics Limited, Stemline Therapeutics, Inc., BioCancell Therapeutics, Inc., AndroScience Corporation, BIND Biosciences, Inc., PharmaMar, S.A., Targa Therapeutics Corp., Cytavis Biopharma GmbH, Polaris Group, Serometrix, LLC, Regulon Inc.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2013
- Prostate Cancer - Pipeline Review, H2 2013
- Non-Small Cell Lung Cancer - Pipeline Review, H2 2013
- Colon Cancer - Pipeline Review, H2 2013
- Liver Cancer - Pipeline Review, H2 2013
- Metastatic Pancreatic Cancer - Pipeline Review, H2 2013
- Cervical Cancer - Pipeline Review, H2 2013
- Metastatic Colorectal Cancer - Pipeline Review, H2 2013
- Head And Neck Cancer - Pipeline Review, H2 2013
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013